The pharmacokinetic parameters (C_max, t_max, AUC_0-​10h, AUC_0-​∞, AUMC_0-​10h, AUMC_0-​∞, MRT, t_0.5 and K_el) of cefadroxil were calcd. following single oral administration of 10 mL (equiv. to 500 mg cefadroxil) of a local generic product (Droxil suspension, The United Pharmaceutical Co., Jordan) and a ref. product (Ultracef suspension, Bristol, USA) to 24 healthy volunteers in a two-​way cross-​over study.  After drug administration, serial blood samples were collected over a period of 10 h.  The concn. of cefadroxil in the sepd. plasma was detd. by using an improved HPLC procedure.  The mean values of C_max, t_max, AUC_0-​10h and t_0.5 were 12.87±2.71 μg​/mL, 1.18±0.31 h, 39.19±5.82 μgh​/mL and 1.73±0.31 h, resp. for Droxil suspension, compared to 13.62±2.62 μg​/mL, 1.27±0.41 h, 41.44±5.56 μgh​/mL and 1.96±0.23 h resp. for Ultracef suspension.  The overall mean relative bioavailability as assessed by the AUC_0-​∞ (Droxil / Ultracef) was 0.95±0.08.  There was no statistical significant difference (P < 0.05) in the plasma concns. or the pharmacokinetic parameters of cefadroxil after administration of the two products indicating that the two products are bioequivalent, and thus the two products are interchangeable.